Ticker history: VTAK became VJET (Flyte Aviation, Inc.) on .
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VTAK SEC filings page.
Catheter Precision, Inc. (VTAK) reported $1.9M in revenue over the twelve months to Jun 30, 2026, up 219.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue nearly doubled, but high gross margins still could not cover operating spending, leaving losses financed externally.
Revenue rose95.0% in FY2025, but the net loss still reached$17.2M , showing that increased sales have not yet translated into operating break-even. Operating cash flow remained negative at$8.3M while financing cash flow added$5.3M , indicating that outside funding was still an important part of the cash model.
R&D consumed
The 0.1x current ratio reflects a severe near-term asset-liability mismatch. Total liabilities of
Financial Health Signals
We do not publish a peer-relative financial health score for Catheter Precision, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Catheter Precision, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Catheter Precision, Inc. reported a net loss of $17.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Catheter Precision, Inc. generated $1.0M in revenue in Q2 2026. This represents an increase of 380.7% from the same quarter a year earlier. Against the prior quarter it is up 135.9%.
Catheter Precision, Inc.'s EBITDA was -$3.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Catheter Precision, Inc. reported a net loss of $3.3M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Catheter Precision, Inc. recorded an outflow of $2.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Catheter Precision, Inc. held $643K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Catheter Precision, Inc.'s gross margin was 9.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 83.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 80.7 percentage points.
Catheter Precision, Inc.'s quarterly ROE was -18.8% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 56.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Catheter Precision, Inc. invested $142K in research and development in Q2 2026. This represents a decrease of 8.4% from the same quarter a year earlier. Against the prior quarter it is down 4.7%.
Catheter Precision, Inc. invested $15K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 114.3% from the same quarter a year earlier. Against the prior quarter it is up 150.0%.
Not reported for Q2 2026.
VTAK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M+380.7% | $432K+202.1% | $238K+59.7% | $226K+135.4% | $212K+128.0% | $143K+74.4% | $149K+16.4% | $96K-27.8% |
| Cost of Revenue | $921K+6478.6% | $42K+281.8% | $20K+81.8% | $18K+80.0% | $14K-12.5% | $11K+120.0% | $11K+57.1% | $10K+66.7% |
| Gross Profit | $98K-50.5% | $390K+195.5% | $218K+58.0% | $208K+141.9% | $198K+157.1% | $132K+71.4% | $138K+14.0% | $86K-32.3% |
| R&D Expenses | $142K-8.4% | $149K+44.7% | $328K+260.4% | $276K+338.1% | $155K+91.4% | $103K+178.4% | $91K | $63K-43.8% |
| SG&A Expenses | $3.9M+35.8% | $2.6M-26.6% | $2.8M-11.0% | $3.0M+2.5% | $2.9M+6.2% | $3.5M+31.2% | $3.1M+13.5% | $2.9M+5.0% |
| Operating Income | -$4.0Mn/m | -$2.3Mn/m | -$9.9Mn/m | -$3.0Mn/m | -$4.7Mn/m | -$3.6Mn/m | -$3.1Mn/m | -$2.9Mn/m |
| EBITDA | -$3.5Mn/m | -$1.9Mn/m | -$9.3Mn/m | -$2.5Mn/m | -$4.2Mn/m | -$3.0Mn/m | -$2.5Mn/m | -$2.3Mn/m |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $32Kn/m |
| Income Tax | -$312Kn/m | -$175Kn/m | -$214K-106.8% | $78Kn/m | -$950Kn/m | -$724Kn/m | $3.1Mn/m | $0n/m |
| Net Income | -$3.3Mn/m | -$1.7Mn/m | -$5.8Mn/m | -$2.3Mn/m | -$5.1Mn/m | -$4.0Mn/m | -$5.6Mn/m | -$4.1Mn/m |
| EPS (Basic) | -$0.92n/m | -$1.39 | -$2.88 | -$1.70 | -$7.28 | -$6.81n/m | N/A | -$38.17 |
Not reported in any period shown, so not listed: EPS (Diluted), Diluted Shares (Avg).
VTAK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $36.9M+44.2% | $35.1M+41.5% | $15.9M-42.9% | $25.5M-4.8% | $25.6M-2.7% | $24.8M-11.5% | $27.8M-9.6% | $26.7M-18.6% |
| Current Assets | $2.5M+22.7% | $1.2M+46.3% | $390K-88.2% | $2.5M+43.9% | $2.0M+427.3% | $854K-56.3% | $3.3M-20.9% | $1.7M-70.3% |
| Cash & Equivalents | $643K-23.3% | $441K-2.0% | $88K-96.9% | $1.1M-15.2% | $838K+5137.5% | $450K-69.8% | $2.9M-19.4% | $1.3M-77.3% |
| Short-Term Investments | $1.2Mn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $88K+83.3% | $62K-12.7% | $86K+160.6% | $34K+6.3% | $48K-23.8% | $71K+12.7% | $33K-25.0% | $32K-50.0% |
| Accounts Receivable | $120K+4.3% | $261K+207.1% | $155K+121.4% | $123K+15.0% | $115K+9.5% | $85K+16.4% | $70K-48.9% | $107K+132.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $13.0M | $9.7M | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $19.7M+3.8% | $25.9M+53.6% | $9.2M-42.5% | $19.0M+36.7% | $19.0M+59.2% | $16.9M+77.8% | $16.0M+67.8% | $13.9M+26.5% |
| Current Liabilities | $13.5M+189.8% | $19.7M+382.7% | $3.9M+75.2% | $5.3M+105.9% | $4.6M+39.9% | $4.1M+74.0% | $2.2M-9.8% | $2.6M+27.1% |
| Non-Current Liabilities | $6.3M-56.3% | $6.2M-51.6% | $5.3M-61.5% | $13.7M+20.9% | $14.4M+66.6% | $12.8M+79.0% | $13.8M+94.9% | $11.3M+26.4% |
| Long-Term Debt | N/A | N/A | $3.1M | $1.5M | $1.5M | N/A | N/A | N/A |
| Total Equity | $17.6M+158.7% | $9.6M+20.9% | $7.1M-40.0% | $6.8M-47.1% | $6.8M-52.6% | $7.9M-57.3% | $11.8M-44.5% | $12.8M-41.3% |
| Retained Earnings | -$314.5Mn/m | -$311.2Mn/m | -$309.5Mn/m | -$303.8Mn/m | -$301.5Mn/m | -$296.4Mn/m | -$292.4Mn/m | -$286.7Mn/m |
VTAK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9Mn/m | -$2.8Mn/m | -$1.5Mn/m | -$2.2Mn/m | -$2.3Mn/m | -$2.3Mn/m | -$2.9Mn/m | -$2.8Mn/m |
| Depreciation & Amortization | $421K-18.7% | $405K-23.7% | $527K-0.8% | $517K-0.4% | $518K+0.6% | $531K+1.7% | $531K+2.7% | $519K+2.0% |
| Stock-Based Compensation | $266K+171.4% | $64K-29.7% | N/A | N/A | $98K+653.8% | $91K+1416.7% | N/A | N/A |
| Capital Expenditures | $15K+114.3% | $6K-40.0% | $0n/m | $0n/m | $7K-84.4% | $10K-54.5% | $0-100.0% | $0-100.0% |
| Free Cash Flow | -$2.9Mn/m | -$2.8Mn/m | -$1.5Mn/m | -$2.2Mn/m | -$2.3Mn/m | -$2.3Mn/m | -$2.9Mn/m | -$2.8Mn/m |
| Investing Cash Flow | -$833Kn/m | -$1.3Mn/m | $218Kn/m | -$28Kn/m | -$13Kn/m | -$10Kn/m | $0n/m | $0n/m |
| Financing Cash Flow | $3.9M+46.2% | $4.5Mn/m | $307K-93.1% | $2.4M-39.1% | $2.7M+897.8% | -$75Kn/m | $4.5Mn/m | $4.0Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VTAK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 9.6%-83.8pp | 90.3%-2.0pp | 91.6%-1.0pp | 92.0%+2.5pp | 93.4%+10.6pp | 92.3%-1.6pp | 92.6%-1.9pp | 89.6%-5.9pp |
| Operating Margin | -388.1% | -536.6% | -4143.3% | -1336.7% | -2210.4% | -2500.0% | -2047.7% | -2978.1% |
| Net Margin | -323.4% | -389.1% | -2427.7% | -996.0% | -2409.9% | -2828.7% | -3777.2% | -4291.7% |
| Return on Equity | -18.8%+56.5pp | -17.6%+33.5pp | -81.9%-34.0pp | -33.2%-1.1pp | -75.3%-45.8pp | -51.1%-36.7pp | -47.9%-44.7pp | -32.1%-23.3pp |
| Return on Assets | -8.9%+11.1pp | -4.8%+11.5pp | -36.4%-16.2pp | -8.8%+6.6pp | -20.0%-3.9pp | -16.3%-6.8pp | -20.3%-18.1pp | -15.4%-9.5pp |
| Current Ratio | 0.19-0.3x | 0.06-0.1x | 0.10-1.4x | 0.46-0.2x | 0.44+0.3x | 0.21-0.6x | 1.48-0.2x | 0.66-2.2x |
| Debt-to-Equity | N/A | N/A | 0.44 | 0.22 | 0.22 | N/A | N/A | N/A |
| Liabilities-to-Equity | 1.12-1.7x | 2.71+0.6x | 1.31-0.1x | 2.81+1.7x | 2.80+2.0x | 2.13+1.6x | 1.36+0.9x | 1.09+0.6x |
| Asset Turnover | 0.030.0x | 0.010.0x | 0.020.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.000.0x |
| FCF Margin | -282.2% | -648.6% | -635.3% | -965.9% | -1070.8% | -1642.0% | -1922.1% | -2883.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Catheter Precision, Inc. VTAK | FY2025 | $819K | -$17.2M | N/A | N/A | — |
| INVO Fertility, Inc. IVF | FY2025 | $6.8M | -$23.3M | N/A | $2.1M | 38/100 |
| Inspire Medical Systems, Inc. INSP | FY2025 | $912.0M | $145.4M | 16.0% | $1.6B | 65/100 |
| InspireMD, Inc. NSPR | FY2025 | $9.0M | -$48.8M | N/A | $29.2M | 50/100 |
| SANUWAVE Health, Inc. SNWV | FY2025 | $44.1M | $11.8M | 26.8% | $12.9M | 61/100 |
| PAVmed Inc. PAVM | FY2025 | $71K | $401K | N/A | $9.1M | — |
Where Catheter Precision, Inc. Ranks
Frequently Asked Questions
Catheter Precision, Inc. (VTAK) reported $819K in total revenue for fiscal year 2025. This represents a 95.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Catheter Precision, Inc. (VTAK) revenue grew by 95.0% year-over-year, from $420K to $819K in fiscal year 2025.
No, Catheter Precision, Inc. (VTAK) reported a net loss of $13.0M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $17.2M.
Catheter Precision, Inc. (VTAK) had EBITDA of -$19.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Catheter Precision, Inc. (VTAK) had $88K in cash and equivalents against $3.1M in long-term debt.
Catheter Precision, Inc. (VTAK) had a gross margin of 92.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Catheter Precision, Inc. (VTAK) has a return on equity of -243.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Catheter Precision, Inc. (VTAK) recorded an outflow of $8.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Catheter Precision, Inc. (VTAK) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Catheter Precision, Inc. (VTAK) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.
Catheter Precision, Inc. (VTAK) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Catheter Precision, Inc. (VTAK) invested $862K in research and development during fiscal year 2025.
Catheter Precision, Inc. (VTAK) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Catheter Precision, Inc. (VTAK) had a debt-to-equity ratio of 0.44 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Catheter Precision, Inc. (VTAK) had a liabilities-to-equity ratio of 1.31 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Catheter Precision, Inc. (VTAK) had a return on assets of -108.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, Catheter Precision, Inc. (VTAK) held $88K in cash, cash equivalents and investments, and reported an operating cash outflow of $8.3M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Catheter Precision, Inc. (VTAK) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Catheter Precision, Inc. (VTAK) reported a net loss of $17.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.